Does GLP-1 Really Work for Weight Loss? Evidence & Biomarkers

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, GLP-1 medications do work for weight loss in clinical settings—but not uniformly across all patients. Recent trials show average weight reductions of 15-22% of baseline body weight over 68 weeks, with some individuals achieving 25%+ reductions. This evidence has reshaped obesity treatment approaches.

The critical question isn't just whether GLP-1 works in general, but whether it's right for your specific metabolic profile. PlexusDx approaches this through precision wellness: understanding your genetic predispositions in key metabolic pathways alongside clinical evidence helps inform a more personalized treatment conversation with your provider.

What Clinical Trials Actually Show About GLP-1 Efficacy

The STEP trials (semaglutide) and SURPASS trials (tirzepatide) provide the largest clinical datasets. Participants receiving semaglutide 2.4 mg weekly lost an average of 14-17% of body weight, while tirzepatide recipients averaged 20-22% reductions. Placebo groups lost 2-3%, underscoring the medication's active role.

Importantly, these results represent group averages. Individual outcomes ranged from 5% weight loss to 30%+ reductions. Baseline metabolic factors, adherence, lifestyle modifications, and genetic variation all influence where a patient falls on this spectrum. Trial data alone cannot predict individual response.

How Metabolic Biomarkers and Genetics Influence GLP-1 Response

Your body's response to GLP-1 depends partly on how your GLP-1 receptors are regulated and how your metabolism processes glucose and appetite signals. Several genetic variants influence these pathways, including the GLP1R gene and the MC4R gene, which affects satiety signaling. Understanding your genetic profile can contextualize expected treatment response.

Biomarker/Genetic Factor	Clinical Relevance to GLP-1 Response
GLP1R rs6923761 variant	May influence baseline GLP-1 receptor expression and treatment sensitivity
MC4R rs17782313 variant	Associated with appetite regulation; variant carriers may have different satiety response
Baseline insulin resistance	Higher baseline IR may predict greater carbohydrate metabolism improvements on GLP-1
Fasting glucose and HbA1c	Baseline metabolic control influences both efficacy expectations and diabetes prevention benefit

Why Individual Response Varies: Beyond Genetics

Genetic predisposition accounts for approximately 30-40% of weight loss variation in GLP-1 treatment. Lifestyle factors—meal composition, physical activity, sleep quality, stress—account for another 30-40%. Medication adherence, gastric tolerance, and compliance with injection or oral dosing schedules significantly impact outcomes.

Patients who achieve the largest weight losses typically combine consistent medication use with dietary modifications and regular activity. Some individuals experience rapid satiety and naturally reduce calorie intake; others require more intentional behavioral change. Provider guidance throughout treatment helps identify which factors may be limiting your progress.

Who Benefits Most From GLP-1 Treatment and Important Safety Considerations

GLP-1 medications are most effective for adults with BMI ≥27 kg/m² with weight-related conditions, or BMI ≥30 kg/m². They also improve glycemic control and reduce cardiovascular events in people with type 2 diabetes. However, they're contraindicated in personal or family history of medullary thyroid cancer or MEN2 syndrome, and should be used cautiously in pregnancy.

Common side effects include nausea, vomiting, constipation, and loss of appetite—most mild and transient. Serious adverse events are rare but include pancreatitis, gallbladder issues, and dehydration. A qualified healthcare provider should evaluate whether GLP-1 treatment is appropriate for your medical history, current medications, and health goals before initiating therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for how your body regulates GLP-1 receptors, glucose metabolism, and appetite-control pathways. The test examines key genetic variants including GLP1R rs6923761, MC4R rs17782313, FTO rs9939609, and GIPR rs1800437—variants associated with metabolic and peptide pathway function. This information should be interpreted with a qualified healthcare provider to inform a more personalized treatment discussion.

The genetic test reveals predispositions in peptide and metabolic pathways, not a definitive prediction of how you'll respond to GLP-1 treatment. Individual genetic variants interact with your lifestyle, baseline health status, and medication adherence. Genetic insights can support a more informed conversation with your provider about whether GLP-1 treatment and which formulation may align with your metabolic profile.

Understanding your genetic context alongside clinical evidence allows you and your provider to make more individualized treatment decisions. If you're considering compounded semaglutide, oral semaglutide, tirzepatide, or other GLP-1 options, discussing your genetic predispositions may help guide dose selection, formulation choice, and expectations for timeline and magnitude of weight loss.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.